Bone Marrow Transplantation最新文献_第4页

Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease. 慢性肉芽肿病患者在霉菌感染情况下进行造血细胞移植的结果。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-04 DOI: 10.1038/s41409-024-02389-x

Ahnika Kline, Mark Parta, Jennifer Cuellar-Rodriguez, Juan Gea-Banacloche, Corin Kelly, Stefania Pittaluga, Christa S Zerbe, Steven M Holland, Harry L Malech, Elizabeth M Kang

{"title":"Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease.","authors":"Ahnika Kline, Mark Parta, Jennifer Cuellar-Rodriguez, Juan Gea-Banacloche, Corin Kelly, Stefania Pittaluga, Christa S Zerbe, Steven M Holland, Harry L Malech, Elizabeth M Kang","doi":"10.1038/s41409-024-02389-x","DOIUrl":"10.1038/s41409-024-02389-x","url":null,"abstract":"Chronic granulomatous disease (CGD) is a disorder of immunity characterized by phagocyte dysfunction. Mold infections in patients with CGD are often severe and disseminated. We present patient characteristics, microbiological data, and outcomes for 26 patients with CGD who received hematopoietic cell transplantation (HCT) or gene therapy-modified cells (GT) between 2008 and 2019, with proven fungal infection either before or during their transplant. All patients engrafted, and all but one GT recipient had neutrophil recovery and evidence of functional correction. Eighteen patients (69%) are currently alive and 19 patients (73% of total, 90% of patients with repeat imaging performed) had evidence of radiographic improvement. With 3 exceptions, deaths were not principally related to the fungal infection and duration of antecedent infection did not correlate with death. Aspergillus species accounted for the majority of disease (50%), followed by Phellinus species (18%). Osteomyelitis and disseminated disease were common, as only 11 patients (42%) had disease restricted to pneumonia. Triazole therapy was used in all 26 patients, with combination therapy used in 25 (96%). HCT or gene therapy, with appropriate antifungal therapy, are viable therapies for refractory fungal infections in patients with CGD.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. 多发性骨髓瘤自体移植（Auto-HCT）后与治疗相关的急性白血病的特征和预后。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-30 DOI: 10.1038/s41409-024-02455-4

Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman, Edward Stadtmauer

{"title":"Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.","authors":"Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman, Edward Stadtmauer","doi":"10.1038/s41409-024-02455-4","DOIUrl":"https://doi.org/10.1038/s41409-024-02455-4","url":null,"abstract":"With a prolonging duration of survivorship, patients with multiple myeloma (MM) who receive high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) have an increased risk of secondary malignancy, most concerning acute leukemia. We retrospectively reviewed the records of all patients with MM who underwent auto-HCT between January 1, 2010, and January 1, 2023, who later developed therapy-related acute leukemia (t-AL). Of 1770 patients with MM who underwent auto-HCT, 18 (1.01%) developed t-AL at a mean interval of 60.0 ± 41.3 months after auto-HCT. The patients with t-AL consisted of 9 (50%) with B-cell acute lymphoblastic leukemia (B-ALL), 8 (44.4%) with acute myeloid leukemia (AML), and 1 (5.6%) with acute promyelocytic leukemia (APML). All patients had received an alkylating agent as part of induction, and the majority received lenalidomide as maintenance therapy. Genetic abnormalities of t-AL were consistent with prior reports. Median overall survival from diagnosis of t-AL was 19.5 months. In patients with t-AL who entered CR, long term survival was common. Further research on predisposing conditions to developing t-AL in patients with MM undergoing auto-HCT is warranted.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. 急性髓性白血病异基因移植前可测量的残留突变 IDH2。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-25 DOI: 10.1038/s41409-024-02449-2

Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan

{"title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.","authors":"Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan","doi":"10.1038/s41409-024-02449-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02449-2","url":null,"abstract":"Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined. A nationwide cohort of 257 adult patients in first remission (CR1) from AML associated with an IDH2 mutation (IDH2m) undergoing allogeneic transplant during the period 2013-2019 in the United States had rates of relapse and survival three years after transplantation of 24% and 71%, respectively. Pre-transplant clinical flow cytometry assessment was not useful in stratifying patients based on risk of post-transplant relapse or death. DNA-sequencing was performed on CR1 blood collected within 100 days before transplant. Persistent detection of IDH2m was common (51%) and associated with increased relapse and death compared to testing negative. Co-mutation at initial diagnosis with mutated NPM1 and/or FLT3-ITD was common in this cohort (41%) and use of these validated MRD markers provided superior stratification compared to IDH2m testing. Patients testing negative for IDH2m prior to transplant had low relapse-related death, regardless of conditioning intensity. Post-transplant relapse rates for those with persistently detectable IDH2m in pre-transplant remission were lower after the FDA approval of enasidenib in August 2017.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT. 欧洲 CAR T 细胞治疗 DLBCL 和 PMBCL 后的严重 ICANS 以及使用左乙拉西坦预防癫痫发作的评估：代表 EBMT 细胞治疗与免疫生物学工作组 (CTIWP) 进行的调查。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-25 DOI: 10.1038/s41409-024-02451-8

Piera Angelillo, Ana Alarcon Tomas, Edoardo Campodonico, Urban Novak, Ludovic Gabellier, Igor Wolfgang Blau, Mi Kwon, Ron Ram, Edouard Forcade, Caroline Besley, Vladan Vucinic, Nicolaus Kröger, Lucía López Corral, Jan Vydra, Silvia Ferrari, Bastian von Tresckow, Marie Therese Rubio, Rafael Hernani, Simona Sica, Friedrich Stölzel, Montserrat Rovira, Eva Wagner-Drouet, Jose Antonio Pérez-Simón, Cristina Castilla-Llorente, Andres J M Ferreri, Jorinde D Hoogenboom, Isabel Sanchez Ortega, Florent Malard, Jürgen Kuball, Annalisa Ruggeri

引用次数: 0

The economic cost of care in poor graft function following allogeneic stem cell transplantation. 异体干细胞移植后移植物功能不良的经济护理成本。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-24 DOI: 10.1038/s41409-024-02452-7

Manu Juneja, Ashvind Prabahran, Mayani Rawicki, Lynette C Y Chee, Rachel M Koldej, David S Ritchie

引用次数: 0

Retraction Note: Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration. 撤稿说明：非粘附性生化间充质干细胞在组织再生中的治疗潜力。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-24 DOI: 10.1038/s41409-024-02441-w

Z L Zhang, J Tong, R N Lu, A M Scutt, D Goltzman, D S Miao

引用次数: 0

Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors. 移植后环磷酰胺与移植后抗胸腺细胞球蛋白可减少HLA匹配的非亲属和单倍体供体外周干细胞移植中的中度至重度慢性移植物抗宿主疾病。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-22 DOI: 10.1038/s41409-024-02436-7

Ying Wang, Wen-Hui Gao, Li-Ning Wang, Ling Wang, Jie-Ling Jiang, Ming Wan, Ai-Bin Liang, Didier Blaise, Jiong Hu

{"title":"Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors.","authors":"Ying Wang, Wen-Hui Gao, Li-Ning Wang, Ling Wang, Jie-Ling Jiang, Ming Wan, Ai-Bin Liang, Didier Blaise, Jiong Hu","doi":"10.1038/s41409-024-02436-7","DOIUrl":"10.1038/s41409-024-02436-7","url":null,"abstract":"Post-transplantation cyclophosphamide (PTCy) has unique advantages for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single-center retrospective landmark analysis, we evaluated chronic GVHD (cGVHD) and clinical outcomes in patients receiving PTCy, tacrolimus, and post-engraftment low-dose anti-thymocyte globulin (PTCy-ATG) as GVHD prophylaxis after HLA-matched unrelated or haploidentical donor transplantation. Two historical patient groups receiving calcineurin inhibitor-based GVHD prophylaxis were used as control groups. A total of 71 patients with myeloid malignancies undergoing allo-HSCT with myeloablative conditioning regimens were included in the analysis. The 3-year cumulative incidences of cGVHD and moderate to severe cGVHD (M/S cGVHD) were 39.2% (95%CI 27.4%-51.0%) and 11.5% (95%CI 4.1%-18.9%), respectively, in the PTCy-ATG group, and only one instance of bronchiolitis obliterans (BO) was observed. The disease-free survival (DFS), overall survival (OS), and GVHD-free and relapse-free survival rates were 94.0% (95%CI 88.3%-99.7%), 93.0% (95%CI 87.1%-98.9%) and 83.8% (95%CI 75.0%-92.6%) respectively. Of note, the PTCy-ATG group presented with a significantly lower incidence of M/S cGVHD and BO, which translated into superior OS in multivariate analysis. In this retrospective analysis, we observed that PTCy-ATG-based GVHD prophylaxis was associated with a lower incidence of M/S cGVHD and better transplantation outcomes beyond day 100, which invites prospective evaluation.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years. 在年龄≥55岁的急性淋巴细胞白血病患者中，异体造血干细胞移植与巩固化疗作为缓解后疗法的比较。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-21 DOI: 10.1038/s41409-024-02448-3

Ling Ma, Rui Ma, Qian Jiang, Hao Jiang, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Xiao-Jun Huang, Yu-Qian Sun

引用次数: 0

Precision medicine results from equitable representation. 精准医疗源于公平代表权。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-21 DOI: 10.1038/s41409-024-02430-z

Alexandra Gomez-Arteaga, Nora Chokr, Jeffery J Auletta

引用次数: 0

Oral malignant and potentially malignant lesions after allogenic hematopoietic cell transplantation: a 10-year follow-up study. 异基因造血细胞移植后的口腔恶性和潜在恶性病变：一项为期 10 年的随访研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-10-19 DOI: 10.1038/s41409-024-02443-8

H Mawardi, S Elad, Y Zadik, M E Correa, O Felemban, N S Treister

引用次数: 0